Irritable Bowel Syndrome Diagnosis: Should There Be Alertness to Cancer?
https://doi.org/10.22416/1382-4376-2019-29-2-76-80
Abstract
Aim. To justify the need to include colorectal cancer (CRC) in the circle of differential diagnostic search for suspected irritable bowel syndrome (IBS).
Background. In accordance with the latest Rome IV criteria for IBS, its diagnosis is mainly based on the assessment of clinical symptoms and objective examination data with a very limited list of additional studies. In this case, colonoscopy for suspected IBS is performed only in patients aged over 50 years old, provided a hereditary predisposition to CRC and the “alarm symptoms” are detected. It has been recently shown that CRC can proceed under the “mask” of IBS. However, colorectal and rectal tumours are often found in patients younger than 50 years old in the absence of hereditary predisposition to CRC and “anxiety symptoms”. This makes it necessary to conduct colonoscopy for all patients with suspected IBS.
Conclusion. The list of diseases requiring differential diagnostics in patients with suspected IBS should always include CRC.
About the Authors
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow
Russian Federation
Dr. Sci. (Med.), Prof., Department of Internal Diseases Propedeutics, Medical faculty
Russian Federation
Dr. Sci. (Med.), Prof., Department of Internal Diseases Propedeutics, Medical faculty
N. L. Jahaya
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow
Russian Federation
Cand. Sci. (Med.), Research Assistant, Department of Internal Diseases Propedeutics, Medical Faculty
Russian Federation
Cand. Sci. (Med.), Research Assistant, Department of Internal Diseases Propedeutics, Medical Faculty
A. V. Sedova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow
Russian Federation
Cand. Sci. (Med.), Research Assistant, Department of Internal Diseases Propedeutics, Medical Faculty
Russian Federation
Cand. Sci. (Med.), Research Assistant, Department of Internal Diseases Propedeutics, Medical Faculty
References
1. Lacy B.E., Mearin F., Chang L. et al. Bowel disorders. Gastroenterology. 2016;150:1393–407.
2. Longstreth G.F., Thompson W.G., Chey W.D. et al. Functional bowel disorders. Gastroenterology. 2016;130:1480–91.
3. Talley N.J. Conquering irritable bowel syndrome. 2 ed. — People’s Medical Publishing House-USA Shelton, Connecticut, 2012. 175 p.
4. Ivashkin V.T., Shelygin Ju.A., Baranskaja E.K. et al. Clinical guidelines for the diagnosis and treatment of patients with irritable bowel syndrome. Rus J. Gastroenterol. Hepatol. Coloproctol. 2014;24(2):92–101 (In Rus.)].
5. Layer P., Andresen V., Pehl C. et al. Guideline irritable bowel syndrome: definition, pathophysiology, diagnosis and therapy. Joint Guideline of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z. Gastroenterol. 49:237–93.
6. Camilleri M. IBS ten years from now: A look into the crystal ball. 21. United European Gastroenterology Week. Berlin, 2013. Oral presentation.
7. Ellis L., Abrahao R., McKinley M. et al. Colorectal cancer incidence trends by age, stage and racial/ethnic group in California, 1990–2014. Cancer Epidemiol Biomarkers Prev. 2008;27(9):1011–8.
8. Ries L.A.G., Eisner M.P., Kosary C.L. et al. Cancer statistics review. 1973–1997, National Cancer Institute. NIH Pub No 00-2789, Bethesda, MD, 2000.
9. Siegel R.L., Jemal A., Ward E.M. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol. Biomarkers Prev. 2009;18(6):1695–8.
10. Myers E.A., Feingold D.L., Forde K.E. et al. Colorectal cancer in patients under 50 years: a retrospective analysis of two institutions’ experience. World J. Gastroenterol. 2013;19(34):5651–7.
11. Scott R.B., Rangel L.E., Osler T.M., Hyman N.H. Rectal cancer in patients under the age of 50 years: the delayed diagnosis. Am. J. Surg. 2016;211(6):1014–8.
12. Winawer S.J., Fletcher R.H., Miller L. et al. Colorectal cancer screening: clinical guidelines and rational. Gastroenterology. 1997;112:594–642.
13. Whitehead W.E., Palsson O.S., Feld A.D. et al. Utility of red flag symptom exclusions in the diagnosis the irritable bowel syndrome. Aliment Pharmacol Ther. 2006;24:137–46.
14. Ford A.C., Veldhuyzen van Zanten S.J., Rodgers C.C. et al. Diagnostic utility of alarm features of colorectal cancer: systematic review and meta-anlysis. Gut. 2008;57(11):1545–53.
15. Juul J.S., Hornung B., Andersen B. et al. The value of using the faecal immunochemical test in general practice on patients presenting with non-alarm symptoms of colorectal cancer. Br J Cancer. 2018;119(4):471–9.
16. Hsiao C.W., Huang W.Y., Ke T.W. et al. Association between irritable bowel syndrome and colorectal cancer: a nationwide population-based study. Eur J Intern Med. 2014;25(1):82–6.
17. Norgaard M., Farkas D.K., Pedersen L. Irritable bowel syndrome and risk of colorectal cancer: a Danish nationwide cohort study. Br J Cancer. 2011;104(7):1202–6.
18. Quach D.T., Hiyama T., Nguyen T.A. et al. Asia-Pacific Colorectal Screening score: A useful tool to stratify risk for colorectal advanced neoplasms in Vietnamese patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2018;33(1):150–5.
19. Thompson W.G. A world-view of IBS. In: Irritable bowel syndrome. Diagnosis and treatment Camilleri M., Spiller R.C. (eds). London, Saunders; 2002:17–26.
20. Shekhar C., Syed Z., Patody N. et al. Prospective survey of functional gastrointestinal disorders in U.K. gastroenterological clinics and its management. 21. United European Gastroenterology Week. Abstracts. UEG Journal. 2013;1(suppl. 1):A242.
Review
For citations:
Sheptulin A.A., Jahaya N.L., Sedova A.V. Irritable Bowel Syndrome Diagnosis: Should There Be Alertness to Cancer? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(2):76-80. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-2-76-80
Views:
3311
Email this article 
